About the Poccardio project
Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients
The PoCCardio project aims to promote personalised treatment of cardiovascular (CV) diseases by identifying CV patients at a high risk and to explore the potential of multifactorial intensified risk factor treatment in lowering cardiovascular risk and recurrent events.
To do so, the project is developing a point-of-care (PoC) tool which uses biological markers and polymorphisms from finger prick blood to help identify, classify and monitor cardiovascular patients at high risk.
The tool will be validated by two trials: a lab validation to evaluate the sensitivity, specificity and robustness of the device in assessing the biomarkers and polymorphisms, followed by a multinational clinical trial to investigate if an intensified, multifactorial risk factor management guided by selected biomarkers measured by the PoC device can reduce the risk of a composite cardiovascular outcome.
Improved management
Personalised treatment strategy & facilitated CV risk factor monitoring
Increased acceptance
Low-cost measurements & rapid determination of risk profile in primary healthcare settings
Validation
Identification of appropriate patients & effective and efficient use of existing pharmaceuticals
The PoCCardio Point-of-care Tool
Enables immediate treatment intensification in routine patient care with adaptation of risk factor control during a single patient visit
The PoCCardio point-of-care tool is a bench-top device tailored to provide a self-contained and portable method of analysing blood samples from patients at treating sites. It can thus facilitate access to advanced diagnosis in areas with limited state-of-the-art equipment.
Through a finger-prick blood sample, the tool will perform measurements for 10 biomarkers and 6 polymorphisms linked with cardiovascular (CV) conditions, converting the sample into a clinically relevant reading, which enables rapid determination of the CV risk profile.
The device brings together biological marker measurements and profiling of genetic variations that are used to enhance risk stratification and provide the affected individuals with personalised care.
The tool limits the amount of expensive reagents and blood samples needed for the tests, and thus reduces both cost and patient’s pain and discomfort. Additionally, use of the tool does not need trained personnel or multi-step tests.
The Consortium
The PoCCardio consortium comprises seven organisations constituting a strong expertise in technical, clinical, and social sciences.
